Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$0.13.

  • Spero Therapeutics' EPS (Basic) rose 5937.5% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.79, marking a year-over-year decrease of 108750.0%. This contributed to the annual value of -$1.27 for FY2024, which is 39533.96% down from last year.
  • Per Spero Therapeutics' latest filing, its EPS (Basic) stood at -$0.13 for Q3 2025, which was up 5937.5% from -$0.03 recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' EPS (Basic) registered a high of $0.97 during Q4 2023, and its lowest value of -$1.01 during Q1 2022.
  • Its 5-year average for EPS (Basic) is -$0.3, with a median of -$0.32 in 2024.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 17948.92% in 2022, then tumbled by 43333.33% in 2024.
  • Over the past 5 years, Spero Therapeutics' EPS (Basic) (Quarter) stood at -$0.92 in 2021, then soared by 179.49% to $0.73 in 2022, then skyrocketed by 32.64% to $0.97 in 2023, then crashed by 138.93% to -$0.38 in 2024, then skyrocketed by 65.58% to -$0.13 in 2025.
  • Its last three reported values are -$0.13 in Q3 2025, -$0.03 for Q2 2025, and -$0.25 during Q1 2025.